Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLYMundipharma presents new data for the inhaled analgesic Penthrox® (methoxyflurane)6 at the European Society for Emergency Medicine (EUSEM)...... 15:05 GMT Tuesday 15th October 2019
Mundipharma: Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana® (canagliflozin) in fast-track procedure Mundipharma welcomes the news that Swissmedic (the Swiss Agency for Therapeutic Products; the surveillance authority for medicines and medical devices in Switzerland) is conducting...... 00:01 GMT Thursday 10th October 2019
Mundipharma Welcomes the New Guidelines from ESC/EASD Recommending First-Line use of Sodium-Glucose Co-transporter-2 Inhibitors for Type 2 Diabetes Patients with Cardiovascular Disease As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), the Mundipharma network of independent associated companies welcomes the ne...... 00:01 GMT Tuesday 3rd September 2019
Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLYAs the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharm...... 00:01 GMT Thursday 22nd August 2019
Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana® (canagliflozin) and...... 08:05 GMT Wednesday 20th March 2019
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Ph...... 13:30 GMT Friday 22nd February 2019
Mundipharma launches Pelmeg®▼(pegfilgrastim) biosimilar in Europe The Mundipharma network of independent associated companies today announced the launch of Pelmeg® (pegfilgrastim), a biosimilar of Neulasta® following Europ...... 12:48 GMT Tuesday 5th February 2019
European Commission Approves Pelmeg▼® (pegfilgrastim) as a Biosimilar Treatment to Reduce the Duration of Neutropenia and Incidence of Febrile Neutropenia in Adults Treated with Chemotherapy The Mundipharma network of independent associated companies today announced that the European Commission (EC) has granted approval for the use of Pelmeg (pegf...... 14:59 GMT Friday 23rd November 2018
flutiform® Receives a Positive Opinion in Europe for the Treatment of Children with Asthma The Mundipharma network of independent associated companies today announced that the European Decentralised Procedure (DCP) licence variation application for...... 11:51 GMT Thursday 8th November 2018
New Guidance From ADA and EASD Recommends Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Patients with Type 2 Diabetes As the European distributor of INVOKANA® (canagliflozin) and VOKANAMET® (canagliflozin and metformin) Mundipharma welcomes the news that SGLT2i’s, includi...... 14:15 GMT Tuesday 16th October 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.